Articles From: BioDelivery Sciences Announces the Hiring of J. Chris Prue as Vice President of Regulatory Affairs and Quality Assurance to BIOLASE to Raise $35 Million from Institutional and Individual Investors in Private Placement


Website and Mobile App Offer Comprehensive Array of Information and Resources to Support Patients and Their Families RALEIGH, N.C. , Dec.
Sign-up for BioDelivery Sciences Launches InReach Support Program for Those Affected by Opioid Dependence investment picks
BUNAVAIL™ (buprenorphine and naloxone) buccal film now available by prescription for the maintenance treatment of opioid dependence Positive top-line results from second Phase 3 BEMA Buprenorphine clinical trial in chronic pain; recent pre-NDA meeting confirmed NDA submission on track for year-end or early 2015 Positive interim analysis completed in Phase 3 trial of Clonidine Topical Gel for painful diabetic neuropathy; Top-line results anticipated by end of first quarter 2015 Agreement signed to develop and commercialize long-acting, injectable, microparticle formulation of buprenorphine for opioid dependence and pain to compliment current portfolio RALEIGH, N.C. , Nov.
Sign-up for BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of Third Quarter 2014 Financials investment picks
Complementary to BUNAVAIL™; Potential to Leverage Current Addiction Sales Force RALEIGH, N.C. , Oct.
Sign-up for BioDelivery Sciences to Develop a Long-Acting Injectable Depot Formulation of Buprenorphine with Evonik for Use in Opioid Dependence and Pain investment picks
RALEIGH, N.C. , Nov.
Sign-up for BioDelivery Sciences to Present at the 26th Annual Piper Jaffray Healthcare Conference investment picks
RALEIGH, N.C. , Nov.
Sign-up for BioDelivery Sciences to Present at the Credit Suisse 2014 Healthcare Conference investment picks
Conference Call Scheduled for Tuesday, October 7 at 8:00 AM Eastern Time RALEIGH, N.C. , Oct.
Sign-up for BioDelivery Sciences to Provide BUNAVAIL Launch Update investment picks
2014/9/25
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1147219&ProfileId=051205&sourceType=1 VIRGINIA BEACH, VA --
Sign-up for BioForce Nanosciences Holdings, Inc. (BFNH) Acquires Two Entities Related to Kale Agriculture investment picks
2014/10/20
DENVER , Oct.
Sign-up for BioFuel Announces Results Of Annual Meeting And Expiration Of Rights Offering investment picks
2014/9/19
DENVER , Sept.
Sign-up for BioFuel Announces Rights Offering investment picks
2014/10/1
DENVER , Oct.
Sign-up for BioFuel Makes Announcement Regarding Rights Offering investment picks
2014/9/23
DENVER , Sept.
Sign-up for BioFuel Makes Announcement Regarding Rights Offering investment picks
By Russ Britt, MarketWatch Stock leaps as new treatment leap past a testing step LOS ANGELES (MarketWatch) -- Plans by Biogen Idec Inc. to move directly from Phase I to Phase III testing on an Alzheimer's treatment boosted shares of the company nearly 7% early Tuesday.
Sign-up for Biogen Alzheimer's drug skips to Phase 3 testing investment picks
2014/10/15
Living with a chronic condition like multiple sclerosis (MS) can be overwhelming for individuals and caregivers who have to balance the challenges of everyday life and work while juggling regular doctors’ visits and medications.
Sign-up for Biogen Idec and Gretchen Rubin Unveil MS BlueprintTM, a New Online Tool to Help People with Multiple Sclerosis Attain Personal Goals investment picks
Biogen Idec (NASDAQ: BIIB) and Swedish Orphan Biovitrum AB (publ) (Sobi) (STO: SOBI) today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) of ELOCTA ™ (rFVIIIFc), a recombinant factor VIII Fc fusion protein product candidate for the treatment of hemophilia A.
Sign-up for Biogen Idec and Sobi Announce European Medicines Agency Validates ELOCTA™ (rFVIIIFc) Marketing Authorization Application for Review investment picks
Biogen Idec (NASDAQ:BIIB) has been named the biotechnology industry leader on the Dow Jones Sustainability World Index (DJSI World). The company also was named to the Dow Jones Sustainability Index (DJSI) North America for the fifth consecutive year, one of only two biotech companies included.
Sign-up for Biogen Idec Named Global Biotechnology Industry Leader on Dow Jones Sustainability World Index investment picks
Biogen Idec Inc. (NASDAQ: BIIB) today reported third quarter 2014 results, including revenue of $2.5 billion, a 37% increase compared to the third quarter of 2013.
Sign-up for Biogen Idec Third Quarter 2014 Revenues Increase 37% to $2.5 Billion investment picks
Biogen Idec Inc. (NASDAQ: BIIB) announced today that it will present at the 2014 Deutsche Bank BioFEST Conference.
Sign-up for Biogen Idec to Present at the 2014 Deutsche Bank BioFEST Conference investment picks
Biogen Idec (NASDAQ: BIIB) will present data supporting its approved hemophilia therapies at the 56 th Annual Meeting of the American Society of Hematology (ASH) taking place in San Francisco, December 6-9.
Sign-up for Biogen Idec to Present Data from Hematology Programs, Including ELOCTATE™ and ALPROLIX® at ASH Annual Meeting investment picks
Shares of Biogen Idec (BIIB) rose 1% in premarket trade Wednesday, after the biotech giant reported better-than-expected third-quarter results and lifted its full-year earnings outlook.
Sign-up for Biogen shares rally after beating profit expectations, raising outlook investment picks
2014/12/2
By Tomi Kilgore NEW YORK (MarketWatch)--Biogen Idec Inc.'s stock rose more than 7% in morning trading Tuesday, after the biotechnology company said it was planning "very aggressively" to start a Phase 3 study program for its Alzheimer's treatment.
Sign-up for Biogen Shares Rise on Outlook for Alzheimer's Treatment investment picks
Shares of Biogen Idec (BIIB) turned lower in premarket trade, and were recently down 3%, with RBC Capital Markets analysts saying third-quarter sales of its key multiple sclerosis treatment, Tecfidera, were below consensus expectations.
Sign-up for Biogen shares turn lower; analyst says key MS drug sales missed expectations investment picks
Biogen Idec's stock (BIIB) jumped 10% in premarket trade Tuesday, after the biotechnology company said it was planning "very aggressively" to start a Phase 3 study program for its Alzheimer's treatment.
Sign-up for Biogen's stock surges on upbeat outlook for Alzheimer's treatment investment picks
BIOLASE, Inc. (NASDAQ:BIOL), the world’s leading manufacturer and distributor of dental lasers, today reported that Alexander K.
Sign-up for Biolase Announces Management Change investment picks
BIOLASE, Inc. (NASDAQ:BIOL), the global leader in dental lasers, today announced a variety of advances and activities for the upcoming Greater New York Dental Meeting 2014 including the introduction of a new generation EPIC X diode laser, designed to be the premier and complete diode laser for the whole dental team.
Sign-up for BIOLASE Introduces a New Commitment to Customer Care, Quality and Innovation at Greater New York Dental Meeting 2014 investment picks
Newest innovation from market-leading dental laser manufacturer optimizes the dental experience for dentists, their staff members and their patients IRVINE, Calif.
Sign-up for BIOLASE Launches New EPIC™ X diode laser in the United States; Now Dentists Can Delight Their Patients, Faster investment picks
BIOLASE, Inc. (NASDAQ:BIOL), the world’s leading manufacturer and distributor of dental lasers, today reported unaudited financial results for the third quarter and nine months ended September 30, 2014.
Sign-up for BIOLASE Reports 2014 Third Quarter Results investment picks
BIOLASE, Inc. (NASDAQ:BIOL), the world’s leading dental laser manufacturer and distributor, announced today that investors including Jack W.
Sign-up for BIOLASE to Raise $35 Million from Institutional and Individual Investors in Private Placement investment picks
Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: BioDelivery Sciences Announces the Hiring of J. Chris Prue as Vice President of Regulatory Affairs and Quality Assurance to BIOLASE to Raise $35 Million from Institutional and Individual Investors in Private Placement
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent